Shares in Ocular Therapeutix (NSDQ:OCUL) rose this morning after the company beat expectations on Wall Street with its fourth quarter earnings, but missed analysts’ sales estimates.
The company is facing a slew of class action suits from investors, as well as a probe by the Securities and Exchange Commission regarding its post-surgical pain relief implant, Dextenza.
Get the full story at our sister site, Drug Delivery Business News.